GB9122820D0 - Stabilised antibodies - Google Patents

Stabilised antibodies

Info

Publication number
GB9122820D0
GB9122820D0 GB919122820A GB9122820A GB9122820D0 GB 9122820 D0 GB9122820 D0 GB 9122820D0 GB 919122820 A GB919122820 A GB 919122820A GB 9122820 A GB9122820 A GB 9122820A GB 9122820 D0 GB9122820 D0 GB 9122820D0
Authority
GB
United Kingdom
Prior art keywords
immunoglobulin
pct
copper ions
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919122820A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10703637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9122820(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GB919122820A priority Critical patent/GB9122820D0/en
Publication of GB9122820D0 publication Critical patent/GB9122820D0/en
Priority to DE69223641T priority patent/DE69223641T2/de
Priority to US08/232,127 priority patent/US5654403A/en
Priority to IL103560A priority patent/IL103560A/en
Priority to AT92922609T priority patent/ATE161191T1/de
Priority to SG1996005153A priority patent/SG47905A1/en
Priority to ES92922609T priority patent/ES2112338T3/es
Priority to EP92922609A priority patent/EP0612251B1/en
Priority to AU28729/92A priority patent/AU674290B2/en
Priority to DK92922609.0T priority patent/DK0612251T3/da
Priority to CA002121257A priority patent/CA2121257C/en
Priority to JP5507258A priority patent/JP2881499B2/ja
Priority to ZA928296A priority patent/ZA928296B/xx
Priority to MYPI92001936A priority patent/MY110207A/en
Priority to PCT/GB1992/001970 priority patent/WO1993008837A1/en
Priority to US08/465,319 priority patent/US5792838A/en
Priority to GR980400101T priority patent/GR3025931T3/el
Priority to HK98103367A priority patent/HK1004325A1/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
GB919122820A 1991-10-28 1991-10-28 Stabilised antibodies Pending GB9122820D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB919122820A GB9122820D0 (en) 1991-10-28 1991-10-28 Stabilised antibodies
MYPI92001936A MY110207A (en) 1991-10-28 1992-10-27 Stabilised antibodies
PCT/GB1992/001970 WO1993008837A1 (en) 1991-10-28 1992-10-27 Stabilised antibodies
EP92922609A EP0612251B1 (en) 1991-10-28 1992-10-27 Stabilised antibodies
CA002121257A CA2121257C (en) 1991-10-28 1992-10-27 Stabilised antibodies
IL103560A IL103560A (en) 1991-10-28 1992-10-27 Metal chelate formulation of antibodies
AT92922609T ATE161191T1 (de) 1991-10-28 1992-10-27 Stabilisierte antikörper
SG1996005153A SG47905A1 (en) 1991-10-28 1992-10-27 Stabilised antibodies
ES92922609T ES2112338T3 (es) 1991-10-28 1992-10-27 Anticuerpos estabilizados.
DE69223641T DE69223641T2 (de) 1991-10-28 1992-10-27 Stabilisierte antikörper
AU28729/92A AU674290B2 (en) 1991-10-28 1992-10-27 Stabilised antibodies
DK92922609.0T DK0612251T3 (da) 1991-10-28 1992-10-27 Stabiliserede antistoffer
US08/232,127 US5654403A (en) 1991-10-28 1992-10-27 Immunoglobulins stabilized with a chelator of copper ions
JP5507258A JP2881499B2 (ja) 1991-10-28 1992-10-27 安定化抗体
ZA928296A ZA928296B (en) 1991-10-28 1992-10-27 Stabilised antibodies
US08/465,319 US5792838A (en) 1991-10-28 1995-06-05 Method for stabilizing immunoglobulin compositions
GR980400101T GR3025931T3 (en) 1991-10-28 1998-01-15 Stabilised antibodies.
HK98103367A HK1004325A1 (en) 1991-10-28 1998-04-22 Stabilised antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919122820A GB9122820D0 (en) 1991-10-28 1991-10-28 Stabilised antibodies

Publications (1)

Publication Number Publication Date
GB9122820D0 true GB9122820D0 (en) 1991-12-11

Family

ID=10703637

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919122820A Pending GB9122820D0 (en) 1991-10-28 1991-10-28 Stabilised antibodies

Country Status (17)

Country Link
US (2) US5654403A (ja)
EP (1) EP0612251B1 (ja)
JP (1) JP2881499B2 (ja)
AT (1) ATE161191T1 (ja)
AU (1) AU674290B2 (ja)
CA (1) CA2121257C (ja)
DE (1) DE69223641T2 (ja)
DK (1) DK0612251T3 (ja)
ES (1) ES2112338T3 (ja)
GB (1) GB9122820D0 (ja)
GR (1) GR3025931T3 (ja)
HK (1) HK1004325A1 (ja)
IL (1) IL103560A (ja)
MY (1) MY110207A (ja)
SG (1) SG47905A1 (ja)
WO (1) WO1993008837A1 (ja)
ZA (1) ZA928296B (ja)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EE04817B1 (et) * 1996-05-24 2007-04-16 Biogen, Incorporated Kudede regeneratsiooni modulaatorid
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2324381C (en) * 1998-04-02 2013-02-26 Cartela Ab An integrin heterodimer and a subunit thereof
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2365601A1 (en) * 1999-03-29 2000-10-05 Kansai Technology Licensing Organization Co., Ltd. Novel cytidine deaminase
DK1914244T3 (da) 1999-04-09 2013-07-22 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler.
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
CA2443330A1 (en) * 2001-04-05 2002-10-17 Toshimitsu Uede Anti-osteopontin antibody and use thereof
BRPI0307702B8 (pt) * 2002-02-14 2021-05-25 Chugai Pharmaceutical Co Ltd formulações de solução contendo anticorpo
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2314604A3 (en) 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2204190A1 (en) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
EP1688432B1 (en) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
WO2005035573A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
JP4809828B2 (ja) 2004-03-30 2011-11-09 グラクソ グループ リミテッド 免疫グロブリン
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP2006249084A (ja) * 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 抗ＭａｄＣＡＭ抗体組成物
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
EP2109623B1 (en) * 2006-05-22 2011-10-12 XBiotech, Inc Treatment of cancer with anti-il-1 antibodies
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
CL2007002881A1 (es) * 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
JP5670318B2 (ja) * 2008-05-30 2015-02-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. インターロイキン１α抗体及び有用な方法
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク，インコーポレイテッドＸｂｉｏｔｅｃｈ，Ｉｎｃ． 病原性単球の標的化
BRPI0921320A2 (pt) * 2008-11-28 2018-05-22 Abbott Laboratories composições de anticorpo estáveis e métodos para estabilizar os mesmos
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
AU2010246168A1 (en) * 2009-05-04 2011-11-10 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-TNF-alpha-antibodies
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
AU2010298264B2 (en) * 2009-09-24 2014-10-23 Xbiotech Inc. Methods, compositions, and kits for reducing anti-antibody responses
CA2778401C (en) * 2009-10-21 2019-08-13 Hiroshima University Integrin alpha 8-beta 1-specific monoclonal antibody
MX339083B (es) 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
JP2013518863A (ja) 2010-02-09 2013-05-23 グラクソ グループ リミテッド 代謝障害の治療
KR101903931B1 (ko) 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
KR102104296B1 (ko) 2010-08-23 2020-04-27 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
HUE029457T2 (en) 2010-11-11 2017-02-28 Abbvie Biotechnology Ltd Liquid formulations containing a high concentration of ANTI-TNF-alpha antibody
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
EP2968550B1 (en) * 2013-03-14 2018-11-14 Ffe Therapeutics LLC Compositions and methods for treating angiogenesis-related disorders
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
FI3334747T3 (fi) 2015-08-13 2023-11-30 Amgen Inc Antigeenia sitovien proteiinien varattu syväsuodatus
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
CN110408600A (zh) * 2018-12-10 2019-11-05 浙江工商大学 一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
CA1308023C (en) * 1988-07-29 1992-09-29 William Austin James Mcauley Immunoglobulin extraction utilizing properties of colloidal solutions
US4933435A (en) * 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin

Also Published As

Publication number Publication date
IL103560A (en) 1998-02-08
CA2121257A1 (en) 1993-05-13
EP0612251A1 (en) 1994-08-31
IL103560A0 (en) 1993-03-15
HK1004325A1 (en) 1998-11-20
AU674290B2 (en) 1996-12-19
DK0612251T3 (da) 1998-04-27
DE69223641T2 (de) 1998-04-09
JPH07502497A (ja) 1995-03-16
SG47905A1 (en) 1998-04-17
US5792838A (en) 1998-08-11
WO1993008837A1 (en) 1993-05-13
JP2881499B2 (ja) 1999-04-12
US5654403A (en) 1997-08-05
CA2121257C (en) 1999-07-13
ZA928296B (en) 1994-04-28
ATE161191T1 (de) 1998-01-15
EP0612251B1 (en) 1997-12-17
AU2872992A (en) 1993-06-07
ES2112338T3 (es) 1998-04-01
MY110207A (en) 1998-02-28
DE69223641D1 (de) 1998-01-29
GR3025931T3 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
ZA928296B (en) Stabilised antibodies
ATE246702T1 (de) Verfahren zur darstellung von oligonukleotiden
GB2279653B (en) Stabilisation of cells with an agent comprising a heavy metal compound
DE69031909D1 (de) Monoklonale antikörper für metall kationen
IE830823L (en) Process and reagent for the determination of low density¹lipoproteins in body fluids
DE3069460D1 (en) Production of immunoglobulin having a high monomer content
FI933546A0 (fi) Kemisk process
IL117157A (en) Preparation of factor ix form biological sources
EP0656419A4 (en) METHOD FOR CLEANING HUMAN SERUM ALBUMINE.
SG86990A1 (en) Process for the quantitative purification of glycolipids
ATE128104T1 (de) Verfahren und vorrichtung zur behandlung eines kaliumchloridgemenges.
AR246526A1 (es) Procedimiento para preparar compuesto de macrolida y composicion que los incluye para combatir plagas excluida su aplicacion en animales y el hombre.
JPS5240494A (en) Process for producing needle crystal fiber of gypsum
DE3650570D1 (de) Verfahren und Reagenz zur Bestimmung des Follikel stimulierenden Hormons sowie hierzu geeignete monoklonale Antikörper
ATE135342T1 (de) Verfahren zur herstellung von diacetylrhein
DE59208022D1 (de) Verfahren zur herstellung von 3(5)-methylpyrazolen
ES2053704T3 (es) Un metodo de estabilizacion de una composicion acuosa consistente en uno o mas anticuerpos monoclonales.
DE69012488D1 (de) Verfahren zur Herstellung von Diamant-Einkristallen durch chemische Dampfabscheidung.
DE3572649D1 (en) A mixture of diastereoisomer compounds, as obtained from (-)-5-(1-hydroxy-1-methylethyl)-2-methyl-2-cyclohexene-1-one, having mucose-cretolytic activity, a process for its preparation and pharmaceutical compositions containing the same
Zhmur On the problem of the distribution of impurity ions in the F-region of the ionosphere
ES8203164A1 (es) Procedimiento para obtener silicio de grado solar